Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke

S.W. Worm, D.A. Kamara, P. Reiss, E. Fontas, S. De Wit, W. El-Sadr, A. D'Arminio Monforte, M. Law, A. Phillips, L. Ryom, F. Dabis, R. Weber, C. Sabin, J.D. Lundgren, Ferran Torres

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)


Concerns have arisen about possible effects of protease inhibitors (PIs) on cardiac conductivity. We found no significant association between current or recent PI exposure and sudden death or nonhemorrhagic stroke (adjusted rate ratio, 1.22; 95% confidence interval,. 95-1.57), whereas cumulative exposure to PIs was associated with an increased risk (adjusted rate ratio, 1.06 per year of exposure; 95% confidence interval, 1.01-1.11). © 2011 The Author.
Original languageEnglish
Pages (from-to)535-539
Number of pages5
JournalJ. Infect. Dis.
Issue number4
Publication statusPublished - Feb 2012


  • cholesterol
  • Human immunodeficiency virus proteinase inhibitor
  • nonnucleoside reverse transcriptase inhibitor
  • RNA directed DNA polymerase inhibitor
  • triacylglycerol
  • adult
  • age distribution
  • article
  • cardiovascular risk
  • cerebrovascular disease
  • cholesterol blood level
  • cohort analysis
  • controlled study
  • disease association
  • drug classification
  • drug exposure
  • drug use
  • female
  • follow up
  • heart infarction
  • human
  • Human immunodeficiency virus infection
  • major clinical study
  • male
  • nonhemorrhagic stroke
  • outcome assessment
  • priority journal
  • risk assessment
  • sex difference
  • sudden death
  • treatment duration
  • triacylglycerol blood level
  • Adult
  • Death, Sudden
  • Female
  • HIV Infections
  • HIV Protease Inhibitors
  • Humans
  • Male
  • Middle Aged
  • Risk Assessment
  • Stroke


Dive into the research topics of 'Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke'. Together they form a unique fingerprint.

Cite this